Next, higher levels of PD-L1 expression were detected in tumor tissue from high-risk group patients, suggesting that patients would benefit more from immune checkpoint inhibitors (ICIs) treatment in this group, even with lower PD1 expression levels (Fig. 6D). This evidence concerns the gene CD274 and neoplasm.